COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

RX-5902 Treatment of Subjects With Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02003092
Recruitment Status : Terminated
First Posted : December 6, 2013
Last Update Posted : January 6, 2020
Information provided by (Responsible Party):
Rexahn Pharmaceuticals, Inc.

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Terminated
Actual Primary Completion Date : October 2019
Actual Study Completion Date : November 2019
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 June 15, 2020
July 2, 2020